Albuterol: Difference between revisions
imported>Howard C. Berkowitz No edit summary |
mNo edit summary |
||
Line 25: | Line 25: | ||
| journal = Medscape Drug Information}}</ref> | | journal = Medscape Drug Information}}</ref> | ||
==References== | ==References== | ||
{{reflist}} | {{reflist}}[[Category:Suggestion Bot Tag]] |
Latest revision as of 07:00, 8 July 2024
![](http://s9.addthis.com/button1-share.gif)
Albuterol is a short-acting adrenergic beta-agonist, widely used in the immediate treatment of symptomatic asthma and other respiratory diseases. It is a "racemic mixture with a 1:1 ratio of the r-isomer, levalbuterol, and s-albuterol, with the chemical name 2-t-Butylamino-1-(4-hydroxy-3-hydroxy-3-hydroxymethyl)phenylethanol. [1]
While most often administered through the respiratory tract using a metered dose inhaler or nebulizer, it also can be given orally.
Uses
Approved indications for the inhaled form include:[2]
- Acute asthma attack
- Asthma prevention
- Bronchitis
- Bronchospasm revention
- Bronchospastic pulmonary disease
- Exercise-induced asthma
- obstructive pulmonary disease
- Emphysema
Off-label uses include: hyperkalemia, familial hyperkalemic periodic paralysis, and respiratory distress in neonates.
Drug comparisons
While it is considered short-acting, its duration of action is longer isoproterenol, is less likely to cause cardiac effects, and as at least as effective as a bronchodilator. [3]
References
- ↑ Anonymous (2024), Albuterol (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ "Albuterol Inh[aled]", Medscape Drug Information
- ↑ "Monograph: Albuterol", Medscape Drug Information